期刊文献+

中晚期鼻咽癌患者CD4+,CD25+T调节细胞及相关调节因子水平的免疫病理意义 被引量:3

Implications of the CD4 ~ and CD25 ~ positive regulatory T cells and its associated regulatory factors in immunopathology of patients with middle to late stage of nasopharyngeal carcinoma
原文传递
导出
摘要 目的探讨中晚期鼻咽癌患者外周血CD4+CD25+T调节细胞比例及转录因子叉头状螺旋转录因子(forkheadtranscriptionfactor3,Foxp3)和血清细胞因子转化生长因子p1(TGF—p1)和IL-10水平的免疫病理意义。方法分别应用流式细胞术(FCM)、逆转录-聚合酶链反应(RT—PCR)、ELISA方法检测中晚期鼻咽癌患者外周血单个核细胞中CD4+CD25+T调节细胞比例、Foxp3转录活性和血清TGF-[31、IL-10表达水平,并与健康人相应指标进行比较,分析其免疫病理意义。结果中晚期鼻咽癌患者外周血CD4+CD25+T调节细胞比例[(4.23±0.53)%V8(2.65±0.31)%,t=8.60,P〈0.01]、Foxp3转录活性(3.699±0.309VS1.109±0.146,t’=31.08,P〈0.05)、TGF—β1[(645.56±39.61)pg/mlvs(488.82±36.91)pg/ml,t=10.27,P〈0.01]及IL—10[(1.27±0.21)pg/mlVS(0.68±0.08)pg/ml,t’=10.61,P〈0.05]表达水平均明显高于健康人。结论CD4+CD25+T调节细胞、转录因子Foxp3和细胞因子TGF-β1、IL-10共同构成一个正反馈体系,促进了中晚期鼻咽癌患者肿瘤微环境中免疫耐受现象的发展及免疫逃逸的发生过程。 Objective To investigate the implications of ratio of the CD4 + and CD25 + positive regulatory T cells ( CD4 + CD25 + Tregs) in peripheral blood mononuclear cells (PBMC) and its associated regulatory factors such as forkhead transcription factor 3 (Foxp3) mRNA transcriptional activity in PBMC, serum levels of transforming growth factor beta-1 ( TGF-β1 ), and interleukin 10 (IL-10) in the immunopathology of patients with middle to late staged nasopharyngeal carcinoma (NPC) based on a clinical trial. Methods In this study, 18 NPC cases at middle to late stage as observing group and 10 healthy persons as con- trol group were included to detect their ratio of the CD4 + CD25 + Tregs in the PBMC with flow cytometry (FCM) technique, transcriptional activity of Foxp3 with RT-PCR procedure, and serum levels of TGF-151 and IL-10 with enzyme-linked immunosorbent assay (ELISA) method. A comparative analysis was used to explore their implications in the immunopathological correlation of NPC cases with their lesion. Results The ratio of the CID4+ CD25 + Tregs to total CID4+ T cells in PBMC was significantly increased [ (4. 23 ± 0. 53) % vs (2. 65 ± 0. 31 ) %, t = 8.60, P 〈 0. 01 ], accompanied with significantly elevated levels of Foxp3 transcription in PBMC (3. 699 ±0. 309 vs 1. 109 ±0. 146, t' =31.08, P 〈0. 05], and serum contents of TGF-β1 [ (645. 56 ± 39. 61 ) pg/ml vs (488. 82 ± 36. 91 ) pg/ml, t = 10. 27, P 〈 0. 01 ] and IL-10 [ ( 1.27±0. 21 ) pg/ml vs (0. 68 ± 0. 08) pg/ml, t' = 10. 61, P 〈 0. 05 ] in these patients, when compared with that of healthy controls. Conclusions It may be true that CID+ CD25 + Tregs, transcriptional regulatory factor Foxp3, and cytokines TGF-β1as well as IL-IO altogether were composed of a regulating system in a positive feedback way to promote the developing process of immunotolerance phenomena in the tumor mi- croenviromnent and the initiation of immunoescape among patients with middle to late staged nasopharyngeal carcinoma.
出处 《中国医师杂志》 CAS 2013年第6期721-724,共4页 Journal of Chinese Physician
基金 国家自然科学基金(No:30572455) 湖南省中医药管理局科研重点项目(No:2010007)
关键词 鼻咽肿瘤 免疫学 鼻咽肿瘤 病理学 T淋巴细胞 调节性 翼螺旋转录因子类转化生长因子B1 白细胞介素10 Nasopharyngeal neoplasms/immunology Nasopharyngeal neoplasms/pathology Tlymphocytes, regulatory Winged-helix transcription factors Transforming growth factor betal Interleukin-lO
  • 相关文献

参考文献8

  • 1Feng X, Li B, Ye H, et al. Increased frequency of CD4^+ CD25 (high) FoxP3^+ regulatory T cells in patients with hepatocellular carcinoma. Arch Immunol Ther Exp (Warsz) ,2011,59(4) :309- 314. doi: 10. 1007/s00005-011-0127-0.
  • 2Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev, 2011,241 ( 1 ) : 260-268. doi: 10. llll/j. 1600-065X. 2011. 01018. x.
  • 3Tian L, Humblet-Baron S, Liston A. Immune tolerance: are regu- latory T cell subsets needed tO explain suppression of autoimmuni- ty? Bioessays, 2012, 34 ( 7 ) : 569-575. doi: 10. 1002/bies. 201100180.
  • 4郭美姿,江华,牛宪萍,邵莉.高龄肝癌患者CD4+CD25+调节性T细胞及转化生长因子-β1检测的临床意义[J].中华老年医学杂志,2012,31(7):589-592. 被引量:2
  • 5Giannelli G, Mazzocca A, Fransvea E, et al. Inhibiting TGF-15 signaling in hepatocellular carcinoma. Biochim Biophys Acta, 2011,1815(2) :214-223. doi: 10. 1016/j. bbcan. 2010.11. 004.
  • 6Cao X. Regulatory T cells and immune tolerance to tumors. Immu- nol Res, 2010, 46 ( 1-3 ) : 79-93. doi: 10. 1007/s12026-009- 8124-7.
  • 7Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble and membrane- bound TGF-lS-mediated regulation of intratumoral T cell differenti- ation and function in B-cell non-Hodgkin lymphoma. PLoS One, 2013,8(3) :e59456. doi: 10. 1371/journal pone. 0059456.
  • 8Hamzavi M, Tadbir AA, Rezvani G, et al. Tissue expression, se- rum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev,2013,14(3 ) : 1681-1685.

二级参考文献3

同被引文献46

  • 1杨孜,王伽略,黄萍,石凌懿,李蓉,叶蓉华,陈蕾.重度子痫前期临床发病类型及特点与围产结局的关系[J].中华妇产科杂志,2006,41(5):302-306. 被引量:155
  • 2谢幸.妇产科学[M].北京:人民卫生出版社,2013:274.
  • 3Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion [ J ]. Science, 2011, 331(624) : 1565-1570. DOI: 10. l126/science. 1203486.
  • 4Chang CS, Chang JH, Hsu NC, et al costimulatory molecules are potential nasopharyngeal carcinoma [ J ]. BMC 10.1186/1471-2407-7-88. Expression of CDS0 and CD86 markers for better survival in Cancer, 2007, 7: 88. DOI:.
  • 5Ren SP, Wang L, Wang H, et al. Gene therapy for human nasopha-ryngeal carcinoma by adenovirus-mediated transfer of human p53, GM-CSF, and B7-1 genes in a mouse xenograft tumor model [ J ]. Cancer Biother Radiopharm, 2008, 23 (5): 591-602. DOI: 10. 1089/ebr. 2007. 0447.
  • 6Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-13 targe- ted cancer therapy[J]. Int J Biol Sci, 2012, 8(7) : 964-978. DOI: 10.7150/ijbs. 4564.
  • 7Hu S, Zhou G, Zhang L, et al. The effects of functional polymor- phisms in the TGF[31 gene on nasopharyngeal carcinoma susceptibili- ty[ J ]. Otolaryngol Head Neck Surg, 2012, 146 (4) : 579-584. DOI : 10.1177/0194599811434890.
  • 8Poh YW, Gan SY, Tan EL. Effects of IL-6, IL-10 and TGF-[3 on the expression of survivin and apoptosis in nasopharyngeal carcinoma TW01 cells[J]. Exp Oncol, 2012, 34(2) : 85-89.
  • 9Flies DB, Sandier BJ, Sznol M, et al. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy[ J ]. Yale J Biol Med, 2011, 84 (4) : 409-421.
  • 10Chen B J, Chapuy B, Ouyang J, et al. PD-L1 expression is charac- teristic of a subset of aggressive B-cell lymphomas and virus-associa- ted malignancies [ J]. Clin Cancer Res, 2013, 19 ( 13 ) : 3462- 3473. DOI: 10. 1158/1078-0432. CCR-13-0855.

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部